Fiztasovimab

Tax included
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV.
MedChemExpress 
HY-P99621

Data sheet

Size
Multiple sizes
Reactivity
CMV
Application
COVID-19-anti-virus
CAS
2467411-25-0